AROA BIOSURGERY LIMITED (ARX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ARX - AROA BIOSURGERY LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: March
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.93
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.63

25 Jul
2024

0.000

OPEN

$0.64

0.000

HIGH

$0.64

183,959

LOW

$0.62

TARGET
$0.975 54.8% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
ARX: 1
Title FY25
Forecast		 FY26
Forecast
EPS (cps) 0.8 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 80.3 xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in NZD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 N/A

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-2.9
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx64.0 M
Book Value Per Share xxxxxxxxxxxxxxx25.3
Net Operating Cash Flow xxxxxxxxxxxxxxx-6.8 M
Net Profit Margin xxxxxxxxxxxxxxx-15.39 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-10.81 %
Return on Invested Capital xxxxxxxxxxxxxxx-10.14 %
Return on Assets xxxxxxxxxxxxxxx-9.35 %
Return on Equity xxxxxxxxxxxxxxx-10.81 %
Return on Total Capital xxxxxxxxxxxxxxx-11.70 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-10.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx6 M
Total Debt xxxxxxxxxxxxxxx7 M
Goodwill - Gross xxxxxxxxxxxxxxx5 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx28 M
Price To Book Value xxxxxxxxxxxxxxx2.19

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx6.5 M
Capex % of Sales xxxxxxxxxxxxxxx10.11 %
Cost of Goods Sold xxxxxxxxxxxxxxx9 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx66 M
Research & Development xxxxxxxxxxxxxxx8 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

24/06/2024

1

Buy

$0.90

42.86%

Bell Potter concludes FY25 for Aroa Biosurgery is anticipated to be a "transformational year", with the company expected to be profitable and generate positive free cash flows, assisted by positive revenue and earnings guidance from FY24.

The broker views the outlook for the company's key products, Myriad and Symphony positively, both are positioned to significantly impact revenues, with the latter’s trial results expected in the 2H25.

Bell Potter points to the competitive pricing strategy and potential for substantial market penetration for Aroa Biosurgery.

The Buy rating and 90c target are maintained. 

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of 0.65 cents.
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of 2.12 cents.
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

3

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Canaccord Genuity

29/05/2024

1

Buy

$1.00

58.73%

As the FY24 results were in line with expectations, showing a total revenue of NZ$69.1m and an EBITDA loss of -NZ$3.1m, Canaccord Genuity has retained its Buy rating for Aroa Biosurgery with an unchanged price target of $1.

As per the broker's comments, strong Myriad sales growth of 73% was noted, though OviTex sales were down -7% YoY. The broker anticipates FY25 to be Aroa’s first profitable year, driven by increased sales productivity and scale, with an expected revenue range of NZ$80-87m.

FY25 EBITDA forecast has been adjusted to NZ$2.4m from NZ$4.3m and FY26 to NZ$14.0m from NZ$11.0m.

FORECAST
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -0.37 cents.
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 1.94 cents.

Jarden

xx/xx/xxxx

2

xxxxxxxxx xx xxxxxxxxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >

ARX STOCK CHART

FNArena News on ARX

1
Rudi’s View: Rate Cuts, Growth & Small Caps

Jul 18 2024 - Rudi's View
2
Rudi’s View: Gold, Healthcare, Staples & Copper

Jul 11 2024 - Rudi's View
3
Australian Broker Call *Extra* Edition – Jun 03, 2024

Jun 03 2024 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – May 29, 2024

May 29 2024 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – May 27, 2024

May 27 2024 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
CSL Shares Breaking Free

Jul 23 2024 - Technicals
2
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
3
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
4
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
5
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
6
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps
7
Dr Boreham’s Crucible: Amplia Therapeutics

Jun 05 2024 - Small Caps
8
Is The Long Wait For CSL About To End?

May 30 2024 - Technicals
9
Dr Boreham’s Crucible: Invion

May 13 2024 - Small Caps
10
Dr Boreham’s Crucible: Race Oncology

Apr 09 2024 - Small Caps